In September of 2022, AlgometRx was awarded two Phase 1 SBIR awards from the National Cancer Institute (NCI) and the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). The NCI award will be used to advance our investigation of Pediatric Vincristine Induced Peripheral Neuropathy (VIPN). The award from NIAMS will further our investigation into the assessment of disease activity in patients with Lupus.
top of page
bottom of page